Efficacy
| Response . | All evaluable∗ (N = 20) . | PTCL-TFH (N = 17) . | ||
|---|---|---|---|---|
| Number . | Percentage . | Number . | Percentage . | |
| Overall response | 15 | 75.0 | 15 | 88.2 |
| CR | 15 | 75.0 | 15 | 88.2 |
| PR | 0 | 0 | 0 | 0 |
| SD | 1 | 5.0 | 0 | 0 |
| PD | 2 | 10.0 | 1 | 5.8 |
| Discontinuation† | 2 | 10.0 | 1 | 5.8 |
| Survival | ||||
| 2-y PFS | 65.8% (95% CI, 43.4-88.1) | 69.2% (95% CI, 46.7-91.7) | ||
| 2-y OS | 68.4% (95% CI, 47.3-89.4) | 76.1% (95% CI, 55.6-96.5) | ||
| Median follow-up | 21.0 mo (range 17.0-33.0) | |||
| Response . | All evaluable∗ (N = 20) . | PTCL-TFH (N = 17) . | ||
|---|---|---|---|---|
| Number . | Percentage . | Number . | Percentage . | |
| Overall response | 15 | 75.0 | 15 | 88.2 |
| CR | 15 | 75.0 | 15 | 88.2 |
| PR | 0 | 0 | 0 | 0 |
| SD | 1 | 5.0 | 0 | 0 |
| PD | 2 | 10.0 | 1 | 5.8 |
| Discontinuation† | 2 | 10.0 | 1 | 5.8 |
| Survival | ||||
| 2-y PFS | 65.8% (95% CI, 43.4-88.1) | 69.2% (95% CI, 46.7-91.7) | ||
| 2-y OS | 68.4% (95% CI, 47.3-89.4) | 76.1% (95% CI, 55.6-96.5) | ||
| Median follow-up | 21.0 mo (range 17.0-33.0) | |||
PD, progression of disease; PR, partial response; SD, stable disease.
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Of the 21 enrolled patients, 1 withdrew consent after 1 cycle of treatment and lost to follow-up.
Discontinuation owing to (1) disease progression and (2) Strongyloides infection.